Response Prediction to Neoadjuvant Chemotherapy: Comparison between Pre-Therapeutic Gene Expression Profiles and In Vitro Chemosensitivity Assay

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Singer, Christian F ^a   Klinglmüller, Florian ^b   Stratmann, Rembert ^c   Staudigl, Christine ^a   Fink Retter, Anneliese ^a   Gschwantler, Daphne ^a   Helmy, Samir ^a   Pfeiler, Georg ^a   Dressler, Anne Catharina ^a   Sartori, Christian ^c   Bilban, Martin ^b  

^a UNIV KLIN FÜR FRAUENHEILKUNDE   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c DCS Innovative Diagnostik Systeme   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; EPIRUBICIN; KI 67 ANTIGEN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CHEMOSENSITIVITY; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MULTIPLE CYCLE TREATMENT; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; PREDICTION; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; TUMOR BIOPSY; TUMOR VOLUME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DRUG SCREENING ASSAYS, ANTITUMOR; EPIRUBICIN; FEMALE; GENE EXPRESSION PROFILING; HUMANS; KI-67 ANTIGEN; NEOADJUVANT THERAPY; PROSPECTIVE STUDIES; TAXOIDS;

EID: 84879468538     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0066573     Document Type: Article

References (34)

1. Gralow JR, Burstein HJ, Wood W, Hortobagyi GN, Gianni L, et al. (2008) Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol 26(5): 814-9.
2. Liedtke C, Mazouni C, Hess KR, André F, Tordai A, et al. (2008) Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26(8): 1275-81.
3. Bear HD, (2010) Neoadjuvant chemotherapy for operable breast cancer: individualizing locoregional and systemic therapy. Surg Oncol Clin N Am. 19(3): 607-26.
4. Keune JD, Jeffe DB, Schootman M, Hoffman A, Gillanders WE, et al. (2010) Accuracy of ultrasonography and mammography in predicting pathologic response after neoadjuvant chemotherapy for breast cancer. Am J Surg 199(4): 477-84.
5. Dowsett M, Dunbier AK, (2008) Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer. Clin Cancer Res 14(24): 8019-26.
6. Miller WR, (2010) Clinical, pathological, proliferative and molecular responses associated with neoadjuvant aromatase inhibitor treatment in breast cancer. J Steroid Biochem Mol Biol 118(4-5): 273-6.
7. Dowsett M, A'Hern R, Salter J, Zabaglo L, Smith IE, (2009) Who would have thought a single Ki67 measurement would predict long-term outcome? Breast Cancer Res. 11Suppl 3: S15.
8. Bottini A, Berruti A, Bersiga A, Brizzi MP, Bruzzi P, et al. (2001) Relationship between tumour shrinkage and reduction in Ki67 expression after primary chemotherapy in human breast cancer. Br J Cancer 19 85(8): 1106-12.
9. Assersohn L, Salter J, Powles TJ, A'hern R, Makris A, et al. (2003) Studies of the potential utility of Ki67 as a predictive molecular marker of clinical response in primary breast cancer. Breast Cancer Res Treat 82(2): 113-23.
10. Takada M, Kataoka A, Toi M, Bando H, Toyama K, et al. (2004) A close association between alteration in growth kinetics by neoadjuvant chemotherapy and survival outcome in primary breast cancer. Int J Oncol 25(2): 397-405.
11. Billgren AM, Rutqvist LE, Tani E, Wilking N, Fornander T, et al. (1999) Proliferating fraction during neoadjuvant chemotherapy of primary breast cancer in relation to objective local response and relapse-free survival. Acta Oncol 38(5): 597-601.
12. Jones RL, Salter J, A'Hern R, Nerurkar A, Parton M, et al. (2009) The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 116(1): 53-68.
13. Lee J, Im YH, Lee SH, Cho EY, Choi YL, et al. (2008) Evaluation of ER and Ki-67 proliferation index as prognostic factors for survival following neoadjuvant chemotherapy with doxorubicin/docetaxel for locally advanced breast cancer. Cancer Chemother Pharmacol 61(4): 569-77.
14. Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, (2005) Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients., et al. J Clin Oncol 20 23(6): 1169-77.
15. Cleator S, Tsimelzon A, Ashworth A, Dowsett M, Dexter T, et al. (2006) Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (cytoxan) (AC) response and resistance. Breast Cancer Res Treat 95(3): 229-33.
16. Kurbacher CM, Cree IA, (2005) Chemosensitivity testing using microplate adenosine triphosphate-based luminescence measurements. Methods Mol Med. 110: 101-20.
17. Solomayer E, Meisner C, Zwirner M, Wallwiener D, Fehm T, et al. (2008) Predicting resistance to platinum-containing chemotherapy with the ATP tumor chemosensitivity assay in primary ovarian cancer. Anticancer Res 28(2A): 949-55.
18. Sharma S, Neale MH, Di Nicolantonio F, Knight LA, Whitehouse PA, et al. (2003) Outcome of ATP-based tumor chemosensitivity assay directed chemotherapy in heavily pre-treated recurrent ovarian carcinoma. BMC Cancer 3 3: 19.
19. Jaffe N, (2006) Measures of Response: RECIST, WHO, and New Alternatives Journal of Clinical Oncology, 24. (20): 3245-3251.
20. Ugurel S, Schadendorf D, Pföhler C, Neuber K, Thoelke A, et al. (2006) In vitro drug sensitivity predicts response and survival after individualized sensitivity-directed chemotherapy in metastatic melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group. Clin Cancer Res 15 12(18): 5454-63.
21. Kurbacher CM, Bruckner HW, Cree IA, Kurbacher JA, Wilhelm L, et al. (1997) Mitoxantrone Combined with Paclitaxel as Salvage Therapy for Platinum-refractory Ovarian Cancer: Laboratory Study and Clinical Pilot Trial, Clinical Cancer Research. 3: 1527-1533.
22. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, et al. (2003) Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4: 249-64.
23. Efron B, (2007) Size, power, and false discovery rates. Ann Statist 35: 1351-1377.
24. Benjamini Y, Hochberg Y, (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society B 57 (1): 289-300.
25. Montagna E, Bagnardi V, Rotmensz N, Viale G, Pruneri G, et al. (2010) Pathological complete response after preoperative systemic therapy and outcome: relevance of clinical and biologic baseline features. Breast Cancer Res Treat 124(3): 689-9.
26. Ueda S, Tsuda H, Saeki T, Osaki A, Shigekawa T, et al. (2010) Early reduction in standardized uptake value after one cycle of neoadjuvant chemotherapy measured by sequential FDG PET/CT is an independent predictor of pathological response of primary breast cancer. Breast J 16(6): 660-2.
27. Groheux D, Giacchetti S, Moretti JL, Porcher R, Espié M, et al. (2011) Correlation of high (18)F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. Eur J Nucl Med Mol Imaging 38(3): 426-35.
28. Ueda S, Tsuda H, Saeki T, Omata J, Osaki A, et al. (2010) Early metabolic response to neoadjuvant letrozole, measured by FDG PET/CT, is correlated with a decrease in the Ki67 labeling index in patients with hormone receptor-positive primary breast cancer: a pilot study. Breast Cancer 18(4): 299-308.
29. Cheang MC, Chia SK, Voduc D, Gao D, Leung S, et al. (2009) Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101(10): 736-50.
30. Azambuja E, Cardoso F, de Castro G Jr, Colozza M, Mano MS, et al. (2997) Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer 96(10): 1504-13.
31. Urruticoechea A, Smith IE, Dowsett M, (2005) Proliferation marker Ki-67 in early breast cancer. J Clin Oncol 23(28): 7212-20.
32. Smith IE, Dowsett M, Ebbs SR, Dixon JM, Skene A, et al. (2005) Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 23(22): 5108-16.
33. Glaysher S, Yiannakis D, Gabriel FG, Johnson P, Polak ME, (2009) Resistance gene expression determines the in vitro chemosensitivity of non-small cell lung cancer (NSCLC). BMC Cancer 27 9: 300.
34. Glaysher S, Gabriel FG, Johnson P, Polak M, Knight LA, et al. (2010) Molecular basis of chemosensitivity of platinum pre-treated ovarian cancer to chemotherapy. Br J Cancer 103(5): 656-62.